Phenol - epa.gov
Symptoms of acute toxicity in humans include irregular breathing, muscle weakness and tremors, loss of coordination, convulsions, coma, and respiratory arrest at lethal doses. (1-3) Acute animal tests in rats, mice, and rabbits have shown phenol to have high acute toxicity from oral exposure. (4) Chronic Effects (Noncancer):
Download Phenol - epa.gov
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
THIS PAGE INTENTIONALLY LEFT BLANK
www.epa.govRed Hill Administrative Order on Consent Scope of Work Deliverable . SECTION 2.2: TANK INSPECTION, REPAIR, AND MAINTENANCE REPORT, dated 11 October 2016
Blanks, This, Pages, This page intentionally left blank, Intentionally, Left
Formaldehyde - US EPA
www.epa.govFormaldehyde . 50-00-0 . Hazard Summary . Formaldehyde is used mainly to produce resins used in particleboard products and as an intermediate in the
EPA Home Water Testing Facts
www.epa.govHome Water Testing Regardless of your water source, here are two situations that may require testing: Do you suspect lead may be in some of your
Fact, Testing, Water, Home, Home water testing facts, Home water testing
27524 Federal Register /Vol. 83, No. …
www.epa.govFederal Register/Vol. 83, No. 114/Wednesday, June 13, 2018/Proposed Rules 27525 1 This became more formalized in 1981 with Executive …
Asbestos Frequently Asked Questions
www.epa.gov7. How do I get certified as an asbestos professional? To become a properly trained and accredited asbestos professional you will need to seek training
Training, Question, Certified, Frequently, Asked, Asbestos, Asbestos frequently asked questions
FY 2019 EPA Budget in Brief
www.epa.govFY 2019 EPA Budget in Brief United States Environmental Protection Agency www.epa.gov
United, States, Protection, Agency, Brief, 2019, Environmental, Budget, Fy 2019 epa budget in brief, Fy 2019 epa budget in brief united states environmental protection agency www
First published in the NeuroLeadership journal
www.epa.govSCARF: a brain-based model for collaborating with and inluencing others First published in the NeuroLeadership journal iSSue oNe 2008 www.NeuroLeadership.org
Based, Model, Brain, Brain based model for collaborating, Collaborating
Method 200.7, Revision 4.4: Determination of Metals …
www.epa.govmethod 200.7 . determination of metals and trace elements in water and wastes by inductively coupled plasma-atomic emission spectrometry revision 4.4
Metal, Determination, Trace, Determination of metals and trace
Effects of Water Age on Distribution System Water …
www.epa.govPrepared by AWWA with assistance from Economic and Engineering Services, Inc. 1 Effects of Water Age on Distribution System Water Quality 1.0 Introduction
System, Quality, Distribution, Water, Age on distribution system water, Age on distribution system water quality
Summary of State Operator Certification Programs …
www.epa.govExecutive Summary Under section 1419(b) of the Safe Drinking Water Act (SDWA), EPA is directed to withhold 20 percent of the funds a state was otherwise entitled to receive under SDWA section 1452 (the
Programs, States, Operator, Summary, Certifications, Summary of state operator certification programs
Related documents
AAFP Chronic Pain Toolkit
www.aafp.orgfor chronic pain will misuse them. 4. The solutions to this . public health crisis include . continued emphasis on . improving chronic pain care, increasing research into pain and pain management ...
Practice Guidelines for Chronic Pain Management
www.asahq.orgChronic Pain Management,” adopted by the ASA in 1996 and published in 1997.1 Methodology A. Definition of Chronic Pain For these Guidelines, chronic pain is defined as pain of any etiology not directly related to neoplastic involvement, asso-ciated with a chronic medical condition or extending in du-
Management, Chronic, Pain, Chronic pain, Chronic pain management
CDC Guideline for Prescribing Opioids for Chronic Pain ...
www.cdc.gov20% of patients presenting to physician offices with noncancer pain symptoms or pain-related diagnoses (including acute and chronic pain) receive an opioid prescription (1). In 2012, health care providers wrote 259 million prescriptions for opioid pain medication, enough for every adult in the United States to have a bottle of pills (2
Guidelines, Opioid, Prescribing, Chronic, Pain, Acute, Noncancer, Guideline for prescribing opioids for chronic pain, Noncancer pain, Acute and chronic pain
Pain Management in Patients with Substance-Use Disorders
www.accp.com3. Design a treatment plan for the management of acute pain in a patient with addiction. 4. Design a pharmacotherapy plan for a patient with coexisting addiction and chronic noncancer pain. 5. Design a pain management plan that encompasses recommended nonpharmacologic components for a patient with a history of substance abuse. Introduction
Management, Chronic, Pain, Acute, Pain management, Noncancer, Management of acute pain, And chronic noncancer pain
GUIDELINES FOR SAFE ADMINISTRATION OF LOW-DOSE …
www.health.pa.govincluding treatment of acute pain in opioid-tolerant patients, treatment of chronic noncancer pain, treatment of severe depression (including patients who are experiencing suicidal ideation), and in palliative care. The purpose of this document is to provide guidance on the safe use of low-dose ketamine in any treatment setting.
Chronic, Pain, Acute, Noncancer, Of acute pain, Chronic noncancer pain
The Impact of Opioids on the Endocrine System
www.mascc.orgChronic Illness Therapy with general and fatigue subscales (FACT-G/FACIT-F)] were all significantly lower in the opioid group than in the controls. A recent study showed that women consuming sustained-action oral or transdermal opioids for the control of noncancer pain have a decrease in FSH and LH accompanied with a profound inhibition of ...
System, Opioid, Endocrine, Chronic, Pain, Noncancer, Noncancer pain, Of opioids on the endocrine system
Buprenorphine Transdermal Delivery System (BUTRANS), C-III
www.pbm.va.gov(OAHK), chronic low back pain (CLBP) or chronic noncancer pain (mainly osteoarthritis and low back pain) in the U.S. and abroad, including the two pivotal multicenter, double-blind, randomized controlled trials in CLBP that the sponsor submitted to the FDA to support marketing approval (Table 1).